Physician profile

Gary W Freeberg

Pulmonary Disease · Great Neck, NY

NPI 1326086208

$20,809.14

in general payments reported to CMS, 2019-2025

43 companies · $2,644 in 2025

The $2,644 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

See the full distribution for Pulmonary Disease

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$8,658.01
Education$59.99

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $4,322.28 2019-2025 Nucala, Trelegy Ellipta, Arexvy
Boehringer Ingelheim Pharmaceuticals, INC. $2,801.91 2019-2025 Ofev, Spiriva Respimat, Stiolto Respimat
Astrazeneca Pharmaceuticals LP $2,655.67 2019-2025 Tezspire, Fasenra, Airsupra
Actelion Pharmaceuticals US, INC. $1,296.86 2019-2025 Opsumit, Uptravi
Genentech USA, INC. $935.04 2019-2024 Xolair
Regeneron Healthcare Solutions, INC. $890.31 2019-2025 Dupixent
Genzyme Corporation $750.66 2020-2025
Insmed, INC. $725.43 2019-2025 Arikayce, Brinsupri
Mylan Specialty L.P. $718.09 2019-2024 Yupelri
Philips North America LLC $688.81 2019-2025 Vest Therapy Und, (Ak6) Vest Therapy
Novartis Pharmaceuticals Corporation $571.48 2019-2024
Electromed, INC. $487.14 2019-2025 Smartvest
Sunovion Pharmaceuticals INC. $419.59 2019-2020
Grifols USA, LLC $397.45 2019-2025 Prolastin-C Liquid
Baxter Healthcare $378.69 2022-2025 Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Verona Pharma, INC. $303.61 2025 Ohtuvayre
Mallinckrodt Hospital Products INC. $239.19 2020-2025 Acthar
Pfizer INC. $226.45 2019-2025
Advanced Respiratory, INC $198.33 2019-2021
Janssen Pharmaceuticals, INC $192.90 2020-2022
Shionogi INC $188.34 2021-2024 Fetroja
Viatris Specialty LLC $140.50 2025 Yupelri
Bayer Healthcare Pharmaceuticals INC. $130.60 2021-2024
Olympus America INC. $125.00 2022
Pulmonx Corporation $124.99 2019
Amgen INC. $117.58 2022-2025 Tezspire
Teva Pharmaceuticals USA, INC. $116.63 2019-2023
Inspire Medical Systems, INC. $92.29 2024-2025 Inspire
Chiesi USA, INC. $76.84 2019-2022
Galvanize Therapeutics, INC $74.90 2024 Aliya System
Intuitive Surgical, INC. $65.54 2024
Merck Sharp & Dohme LLC $56.95 2019-2023 Verquvo, Vaxneuvance, Pneumovax 23
United Therapeutics Corporation $51.12 2025 Tyvaso
Zoll Respicardia, INC. $48.26 2023 Remede System
Takeda Pharmaceuticals U.S.A., INC. $29.95 2022
Mallinckrodt Enterprises LLC $26.96 2019
Alexion Pharmaceuticals, INC. $24.26 2023 Ultomiris
Covis Pharma Gmbh $22.22 2022
Melinta Therapeutics, LLC $21.06 2023 Vabomere, Rezzayo, Kimyrsa
Circassia INC. $19.51 2019
Cumberland Pharmaceuticals, INC. $18.69 2020
E.R. Squibb & Sons, L.L.C. $18.64 2020
Phadia US INC. $18.42 2023 Immunocap

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gary W Freeberg

$20,809.14

in general payments reported 2019-2025

Years
2019-2025
Top company
Glaxosmithkline, LLC.
Context
The $2,644 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/241009/gary-w-freeberg

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.